ValirX gets new European grant for cancer screening biomarker
ValiRx (LON:VAL) has received European patent approval for its cancer screening test biomarker NAV3. The test enables cancer cells to be detected in tissue samples at a stage where tumour development...
View ArticleValiRx's stake sale provides cash run-way, says Daniel Stewart
The proceeds from ValiRx's (LON:VAL) VolitionRx stake sale along with recent fundraising strengthens the firm's balance sheet and provides a cash run-way into 2015, reckons house broker Daniel Stewart....
View ArticleValiRx cashes in on VolitionRx stake
Drug developer ValiRx (LON:VAL) has sold its shareholding in VolitionRx. The life sciences firm offloaded 510,811 shares, netting US$601,578. The funds will be used to continue clinical development of...
View ArticleValiRx interims reveal a period of 'encouraging progress'
Life sciences group ValiRx (LON:VAL) has confirmed it expects to release results from the clinical trial of its lead drug in December. VAL 201 is currently undergoing first-in-man studies on cancer...
View ArticleValiRx's €1.6mln Eurostars grant provides endorsement of its technology
ValiRx (LON:VAL) said it and Pharmatest Services will share a new Eurostars grant worth up to €1.6mln that will fund pre-clinical studies on its drug candidate VAL101, which regulates rebellious genes....
View ArticleValiRx's lead compound trial progresses on schedule
Drug developer ValiRx (LON:VAL) is making steady progress with the first in-man studies for lead compound VAL201. The phase I trial is to assess tolerability and safety of the prostate cancer treatment...
View ArticleUPDATE- ValiRx agrees details of cancer study
---ADDS QUOTES FROM COMPANY, SHARE PRICE--- ValiRx (LON:VAL) said its agreed an expanded and adaptive protocol for its first-in-man studies on VAL 201, its drug candidate being developed for prostate...
View ArticleValiRx looks to social impact market as becomes founder member of new exchange
Cancer focused diagnostic specialist ValiRx (LON:VAL) is looking forward to being a member of the new Social Stock Exchange (SSE), where investors can learn more about firms with social and...
View ArticleValiRx granted patent in Australia for top compound
ValiRx (LON:VAL) has been granted patent protection in Australia for VAL201, its lead therapeutic compound that targets at a range of cancers. The company already has full, worldwide rights and...
View ArticleValiRx given international showcase at prestigious American cancer event
The drug developer ValiRx (LON:VAL) has been asked to give a presentation at the prestigious American Association for Cancer Research Conference in Washington starting this Saturday (April 6)....
View ArticleValiRx appoints chief commercial officer
Drug developer and diagnostics specialist ValiRx (LON:VAL) has appointed a chief commercial officer. He is Samuel Ogunsalu, former head of commercialisation and the sector specialist for life...
View ArticleValiRx appoints experienced medical monitoring officer for VAL201
Life sciences company ValiRx (LON:VAL) has unveiled Dr Alan Boyd as medical monitoring officer for the clinical development of VAL201. The company said the pharmaceutical physician will oversee the...
View ArticleValiRx gears up for phase I clinical trials after £2 mln cash injection
Life sciences group ValiRx (LON:VAL) said the recent £2.03 mln cash call allows it to take VAL201 through first human clinical trials. It is hoped this potentially breakthrough treatment for cancer...
View ArticleValirX to raise £2.03 million to take VAL201 through first clinical trial
ValiRx (LON:VAL) is raising £2.03 million to take its VAL 201 candidate, targeting cancer, through its first clinical trial. The study aims to demonstrate that the compound is safe and show the...
View ArticleValiRx's lead compound has impact in breast cancer study
Drug developer ValiRx (LON:VAL) has had more good news from its lead compound VAL201, which has now shown well in a breast cancer study after encouraging prostate cancer data earlier. ValiRx said...
View ArticleValiRx technology has potential for "wide range" of treatments
ValiRx (LON:VAL) said today it has made progress in all areas of the business after completing a two year international grant programme for its gene-silencing technology. ValiRx has been the leader...
View ArticleMellon looks at potential new medicines which could transform society - Pt 2
He built a reputation for being a being a savvy investor in emerging markets and mining, and in doing so amassed a personal fortune in excess of £500 million. Now Jim Mellon is turning his attention to...
View ArticleValiRx shares soar as reveals highly encouraging cancer study results
Shares in drug developer ValiRx (LON:VAL) soared 40 per cent today after encouraging results from an independent late pre-clinical study on its lead cancer compound VAL201. The data showed it...
View ArticleValiRx reveals highly encouraging cancer study results
Drug developer ValiRx (LON:VAL) this morning released what can only be described as highly encouraging results from an independent late pre-clinical study on cancer compound VAL201. The data showed it...
View ArticleValiRx wins new US patent for cancer screening gene biomarker
ValiRx (LON:VAL), a life science company with a focus on cancer diagnostics and therapeutics for personalised medicine, said it has been granted a patent in the US for a cancer screening method, using...
View Article
![Ruthie Foster – Just Say Yes (2026) [24-bit FLAC]](http://imageurl.xyz/images/2026/08/27/Ruthie_Foster-Just_Say_Yes-24BIT-WEB-FLAC-2026-ENRiCH.jpg)
